Edward B Garon1, Tudor-Eliade Ciuleanu2, Oscar Arrieta3, Kumar Prabhash4, Konstantinos N Syrigos5, Tuncay Goksel6, Keunchil Park7, Vera Gorbunova8, Ruben Dario Kowalyszyn9, Joanna Pikiel10, Grzegorz Czyzewicz11, Sergey V Orlov12, Conrad R Lewanski13, Michael Thomas14, Paolo Bidoli15, Shaker Dakhil16, Steven Gans17, Joo-Hang Kim18, Alexandru Grigorescu19, Nina Karaseva20, Martin Reck21, Federico Cappuzzo22, Ekaterine Alexandris23, Andreas Sashegyi24, Sergey Yurasov23, Maurice Pérol25. 1. David Geffen School of Medicine at UCLA/Translational Research in Oncology-US Network, Los Angeles, CA, USA. Electronic address: egaron@mednet.ucla.edu. 2. Institute of Oncology Ion Chiricuta and University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. 3. Instituto Nacional de Cancerologia (INCAN), Mexico City, Mexico. 4. Tata Memorial Centre, Mumbai, India. 5. Oncology Unit GPP, Sotiria General Hospital, Athens School of Medicine, Athens, Greece. 6. Ege University School of Medicine, Izmir, Turkey. 7. Department of Medicine, Division of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 8. Department of Chemotherapy, N N Blokhin Cancer Research Center, Moscow, Russia. 9. Centro de Investigaciones Clínicas, Clínica Viedma, Argentina. 10. Wojewódzkie Centrum Onkologii, Gdansk, Poland. 11. Chemotherapy Department, John Paul II Hospital, Krakow, Poland. 12. Pavlov State Medical University, St Petersburg, Russia. 13. Charing Cross Hospital, London, UK. 14. Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany. 15. Medical Oncology, San Gerardo Hospital, Monza, Italy. 16. Cancer Center of Kansas, Wichita, KS, USA. 17. St Jansdal Hospital, Herderwijk, Netherlands. 18. Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea. 19. Department of Medical Oncology, Institute of Oncology, Bucharest, Romania. 20. City Clinical Oncology Dispensary, St Petersburg, Russia. 21. LungenClinic Grosshansdorf, German Center for Lung Research (DZL), Grosshansdorf, Germany. 22. Istituto Toscano Tumori, Livorno, Italy. 23. ImClone Systems, Eli Lilly, Bridgewater, NJ, USA. 24. Eli Lilly, Indianapolis, IN, USA. 25. Léon-Bérard Cancer Centre, Lyon, France.
Abstract
BACKGROUND:Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. METHODS: In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973. FINDINGS: Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocatedramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care. INTERPRETATION:Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. FUNDING: Eli Lilly.
RCT Entities:
BACKGROUND:Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy. METHODS: In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973. FINDINGS: Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocated ramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care. INTERPRETATION:Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC. FUNDING: Eli Lilly.
Authors: José Baselga; Nina Bhardwaj; Lewis C Cantley; Ronald DeMatteo; Raymond N DuBois; Margaret Foti; Susan M Gapstur; William C Hahn; Lee J Helman; Roy A Jensen; Electra D Paskett; Theodore S Lawrence; Stuart G Lutzker; Eva Szabo Journal: Clin Cancer Res Date: 2015-10-01 Impact factor: 12.531
Authors: Marissa Mayor; Neng Yang; Daniel Sterman; David R Jones; Prasad S Adusumilli Journal: Eur J Cardiothorac Surg Date: 2015-10-29 Impact factor: 4.191
Authors: Y Shimodaira; E Elimova; R Wadhwa; H Shiozaki; N Charalampakis; V Planjery; J E Rogers; S Song; J A Ajani Journal: Expert Opin Orphan Drugs Date: 2015-05-25 Impact factor: 0.694